FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition
This article was originally published in The Tan Sheet
FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs
You may also be interested in...
Researchers say their literature review shows gaps in the data supporting topical vitamins' prevention and treatment of skin aging
FDA under the Obama administration may cast a sharper eye on cosmeceuticals than the agency has in years past, according to Georgia C. Ravitz, a food and drug law lawyer at Arent Fox
Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.